Anticancer therapy SMRT-ens up: targeting the BCL6-SMRT interaction in B cell lymphoma

Cancer Cell. 2010 Apr 13;17(4):315-6. doi: 10.1016/j.ccr.2010.03.012.

Abstract

Transcription factors have proven to be difficult targets for the development of small-molecule drugs. In this issue of Cancer Cell, Cerchietti et al. identify and characterize a specific, small-molecule inhibitor of BCL6, an oncogenic transcriptional repressor, that has high clinical promise for treating diffuse large B cell lymphoma.

Publication types

  • Comment

MeSH terms

  • DNA-Binding Proteins / antagonists & inhibitors*
  • Humans
  • Lymphoma, B-Cell / drug therapy*
  • Lymphoma, B-Cell / genetics
  • Lymphoma, B-Cell / physiopathology
  • Nuclear Receptor Co-Repressor 2 / genetics
  • Nuclear Receptor Co-Repressor 2 / physiology
  • Nuclear Receptor Co-Repressor 2 / therapeutic use*
  • Precision Medicine / trends
  • Proto-Oncogene Proteins c-bcl-6

Substances

  • BCL6 protein, human
  • DNA-Binding Proteins
  • NCOR2 protein, human
  • Nuclear Receptor Co-Repressor 2
  • Proto-Oncogene Proteins c-bcl-6